Compare TPC & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TPC | GPCR |
|---|---|---|
| Founded | 1894 | 2016 |
| Country | United States | United States |
| Employees | N/A | 233 |
| Industry | General Bldg Contractors - Nonresidential Bldgs | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.8B |
| IPO Year | 2003 | 2023 |
| Metric | TPC | GPCR |
|---|---|---|
| Price | $96.59 | $54.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $86.00 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 749.6K | 516.8K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | ★ 148.24 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $5,543,039,000.00 | N/A |
| Revenue This Year | $15.37 | N/A |
| Revenue Next Year | $9.99 | N/A |
| P/E Ratio | $55.32 | ★ N/A |
| Revenue Growth | ★ 28.11 | N/A |
| 52 Week Low | $53.83 | $18.26 |
| 52 Week High | $102.30 | $94.90 |
| Indicator | TPC | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 64.91 | 61.77 |
| Support Level | $76.66 | $43.76 |
| Resistance Level | $101.15 | $57.15 |
| Average True Range (ATR) | 4.19 | 2.39 |
| MACD | 0.86 | 0.43 |
| Stochastic Oscillator | 78.51 | 93.26 |
Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically it derives key revenue from the United States.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.